Grünenthal is a global leader in pain management. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Company

A world free of pain. This is our shared vision. To bring it to life, we execute our strategy and work on our company’s culture – everyday, everywhere, every one of us.

... We are Grünenthal

Grünenthal’s product portfolio, brands, ingredients and indication range.

... Products

A mix of strong entrepreneurial spirit, close collaboration, and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.

... Leadership

The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit.

... Supervisory Board

Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Partnering

In view of our vision of a World Free of Pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.

... Global presence & sites

Although firmly rooted in Germany, today we are very much a growing global Business.

... History

Explore our media section and access a range of materials relating to our company.

... Media

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.

... Our Stories

In this section you will find both current and archived press releases published from 2019 onwards by Grünenthal GmbH, Germany.

... Press releases

... Statements

Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .

... Corporate publications

Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures.

... Image resources

The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting.

... Video resources

Our products

Please note that indications and formulations may vary from country to country. Please refer to the respective local product information or Summary of Product Characteristics (SmPC).

Active ingredient / Technology	Brand name	Indication range*
Capsaicin	Qutenza^®	EU indication: Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain. US indication: Treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.
Fixed-dose combination of Esomeprazole and Naproxen	Vimovo^®	In adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.
Lidocaine	Versatis^®	EU and Peru indication: Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (postherpetic neuralgia, PHN) in adults. Latin America indication: Treatment of localised neuropathic pain, including pain associated with a previous herpes zoster infection (postherpetic neuralgia).
Zolmitriptan	Zomig^® AscoTop^®Nasal	Oral formulations: In adults aged 18 years and older for acute treatment of migraine headache with or without aura. Nasal spray: In adults and adolescents aged 12 years and older for the acute treatment of migraine headache with or without aura, and in adults for the treatment of cluster headache.***
Testosterone undecanoate	Nebido^®	Treatment of male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests.
Esomeprazole	Nexium^®	20 mg; 40 mg gastro-resistant tablets: Indicated in adults for: Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (GERD) In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and: - healing of Helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers Patients requiring continued NSAID therapy: - healing of gastric ulcers associated with NSAID therapy - Prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers. Treatment of Zollinger Ellison Syndrome Indicated in adolescents from the age of 12 years for: Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (GERD) In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori Nexium™ is also available in other dosage forms with slightly varying indications.^#
Rosuvastatin	Crestor^®	Treatment of hypercholesterolaemia Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate. Adults, adolescents and children aged 6 years or older with homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate. Prevention of cardiovascular events Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.

^*Status: January 2024. If not otherwise mentioned the EU SmPC approved at the time of review is used as a basis. Please note that indications and formulations may vary from country to country.
Please refer to the respective local product information or Summary of Product Characteristics (SmPC)
^*** Indication in UK: Zomig Nasal Spray is indicated for the acute treatment of migraine with or without aura.
^# see SmPC for ‘Nexium™ 10 mg gastro-resistant granules for oral suspension, sachet’ and for ‘Nexium™ 40 mg Powder for solution for injection/infusion’

Overview of medication that contains an opioid mechanism of action

Our products

We have been striving to provide solutions for patients with large unmet medical needs for over seven decades. If you are a healthcare professional, find out what we have achieved to date by exploring our product portfolio and visiting the Grünenthal Health website.

Visit Grünenthal Health